Vujosevic, Stela
Parra, M. Margarita
Hartnett, M. Elizabeth
O’Toole, Louise http://orcid.org/0000-0003-4851-0918
Nuzzi, Alessia http://orcid.org/0000-0003-3929-175X
Limoli, Celeste
Villani, Edoardo
Nucci, Paolo
Article History
Received: 26 November 2021
Revised: 10 March 2022
Accepted: 31 March 2022
First Online: 15 April 2022
Change Date: 12 May 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41433-022-02083-6
Competing interests
: SV: Abbvie-Allergan, Apellis, Bayer, Novartis, Roche SPA: Advisory Board participation MMP: none MEH: This work was supported by the National Institutes of Health EY014800 and an Unrestricted Grant from Research to Prevent Blindness, Inc., New York, NY, to the Department of Ophthalmology & Visual Sciences, University of Utah; and the National Institutes of Health R01EY015130 and R01EY017011 to MEH. LO’T: Bayer and Novartis: Advisory Board participation. AN: none. Celeste Limoli: none. EV: Allergan: Consultant/Advisor, Lecture fees, Grant support (AAO Financial Disclosure and First-slide Policy 2021); FB Vision and Santen: Consultant/Advisor, Lecture fees; Bruschettini, Oftagest, Sooft, Thea and Visufarma: Lecture fees; Alfa intes, OffHealth, Servimed and Shire: Grant support (AAO Financial Disclosure and First-slide Policy 2021). PN: none.
Free to read: This content has been made available to all.